Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gynecological carcinosarcomas: Overview and future perspectives.
Collet L, González López AM, Romeo C, Méeus P, Chopin N, Rossi L, Rowinski E, Serre AA, Rannou C, Buisson A, Treilleux I, Ray-Coquard I. Collet L, et al. Bull Cancer. 2023 Nov;110(11):1215-1226. doi: 10.1016/j.bulcan.2023.07.005. Epub 2023 Sep 9. Bull Cancer. 2023. PMID: 37679206
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.
Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, de la Motte Rouge T, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M. Becker O, et al. Among authors: collet l. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005815. doi: 10.1136/ijgc-2024-005815. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39481880
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Vienne A, Collet L, Chevalier T, Borel C, Tardy M, Huguet F, Richard S, Salas S, Saada-Bouzid E, Fayette J, Daste A. Vienne A, et al. Among authors: collet l. BMC Cancer. 2023 Jul 14;23(1):663. doi: 10.1186/s12885-023-11133-5. BMC Cancer. 2023. PMID: 37452287 Free PMC article.
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Collet L, Eberst L, Ludovic G, Debled M, Hrab L, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T. Collet L, et al. Breast Cancer. 2023 Mar;30(2):329-341. doi: 10.1007/s12282-022-01427-0. Epub 2023 Jan 11. Breast Cancer. 2023. PMID: 36630013
Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation.
Pujol P, Yauy K, Coffy A, Duforet-Frebourg N, Gabteni S, Daurès JP, Penault Llorca F, Thomas F, Hughes K, Turnbull C, Galibert V, Rideau C, Corsini C, Collet L, You B, Geneviève D, Philippe N. Pujol P, et al. Among authors: collet l. Cancers (Basel). 2022 Jul 4;14(13):3266. doi: 10.3390/cancers14133266. Cancers (Basel). 2022. PMID: 35805038 Free PMC article.
339 results